Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
05
02
2021
accepted:
27
09
2021
pubmed:
25
12
2021
medline:
23
2
2022
entrez:
24
12
2021
Statut:
ppublish
Résumé
Expansions of a G
Identifiants
pubmed: 34949835
doi: 10.1038/s41591-021-01557-6
pii: 10.1038/s41591-021-01557-6
pmc: PMC8861976
mid: NIHMS1779498
doi:
Substances chimiques
C9orf72 Protein
0
Oligonucleotides, Antisense
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-124Subventions
Organisme : NINDS NIH HHS
ID : R01 NS111990
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001453
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Dejesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245–256 (2011).
pubmed: 21944778
pmcid: 3202986
doi: 10.1016/j.neuron.2011.09.011
Renton, A. E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257–268 (2011).
pubmed: 21944779
pmcid: 3200438
doi: 10.1016/j.neuron.2011.09.010
Cook, C. & Petrucelli, L. Genetic convergence brings clarity to the enigmatic red line in ALS. Neuron 101, 1057–1069 (2019).
pubmed: 30897357
doi: 10.1016/j.neuron.2019.02.032
Amick, J. & Ferguson, S. M. C9orf72: at the intersection of lysosome cell biology and neurodegenerative disease. Traffic 18, 267–276 (2017).
pubmed: 28266105
pmcid: 5389918
doi: 10.1111/tra.12477
Belzil, V. V. et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol. 126, 895–905 (2013).
pubmed: 24166615
pmcid: 3830740
doi: 10.1007/s00401-013-1199-1
Zhu, Q. et al. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat. Neurosci. 23, 615–624 (2020).
pubmed: 32284607
pmcid: 7384305
doi: 10.1038/s41593-020-0619-5
O’Rourke, J. G. et al. C9orf72 is required for proper macrophage and microglial function in mice. Science 351, 1324–1329 (2016).
pubmed: 26989253
pmcid: 5120541
doi: 10.1126/science.aaf1064
Burberry, A. et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci. Transl. Med. 8, 347ra393 (2016).
doi: 10.1126/scitranslmed.aaf6038
Shi, Y. et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med. 24, 313–325 (2018).
pubmed: 29400714
pmcid: 6112156
doi: 10.1038/nm.4490
Ash, P. E. et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639–646 (2013).
pubmed: 23415312
pmcid: 3593233
doi: 10.1016/j.neuron.2013.02.004
Mori, K. et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335–1338 (2013).
pubmed: 23393093
doi: 10.1126/science.1232927
Mizielinska, S. et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345, 1192–1194 (2014).
pubmed: 25103406
pmcid: 4944841
doi: 10.1126/science.1256800
Tao, Z. et al. Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. Hum. Mol. Genet. 24, 2426–2441 (2015).
pubmed: 25575510
doi: 10.1093/hmg/ddv005
Freibaum, B. D. et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525, 129–133 (2015).
pubmed: 26308899
pmcid: 4631399
doi: 10.1038/nature14974
Loveland, A.B. et al. Ribosome inhibition by C9orf72-ALS/FTD poly-PR and poly-GR proteins revealed by cryo-EM. Preprint at https://www.biorxiv.org/content/10.1101/2020.08.30.274597v1 (2020).
Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238–248 (2017).
pubmed: 28244990
pmcid: 5517098
doi: 10.1038/nbt.3765
Jafar-Nejad, P. et al. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration. Nucleic Acids Res. 49, 657–673 (2020).
pmcid: 7826274
doi: 10.1093/nar/gkaa1235
Peters, O. M. et al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron 88, 902–909 (2015).
pubmed: 26637797
pmcid: 4828340
doi: 10.1016/j.neuron.2015.11.018
O’Rourke, J. G. et al. C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron 88, 892–901 (2015).
pubmed: 26637796
pmcid: 4672384
doi: 10.1016/j.neuron.2015.10.027
Donnelly, C. J. et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415–428 (2013).
pubmed: 24139042
pmcid: 4098943
doi: 10.1016/j.neuron.2013.10.015
Sareen, D. et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 5, 208ra149 (2013).
pubmed: 24154603
pmcid: 4090945
doi: 10.1126/scitranslmed.3007529
Lagier-Tourenne, C. et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA 110, E4530–E4539 (2013).
pubmed: 24170860
pmcid: 3839752
doi: 10.1073/pnas.1318835110
Jiang, J. et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron 90, 535–550 (2016).
pubmed: 27112497
pmcid: 4860075
doi: 10.1016/j.neuron.2016.04.006
Gendron, T. F. et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci. Transl. Med. 9, eaai7866 (2017).
pubmed: 28356511
pmcid: 5576451
doi: 10.1126/scitranslmed.aai7866
Cook, C. N. et al. C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Sci. Transl. Med. 12, eabb3774 (2020).
pubmed: 32878979
pmcid: 7989020
doi: 10.1126/scitranslmed.abb3774
Zhang, K. et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56–61 (2015).
pubmed: 26308891
pmcid: 4800742
doi: 10.1038/nature14973
Almeida, S. et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 126, 385–399 (2013).
pubmed: 23836290
pmcid: 3753484
doi: 10.1007/s00401-013-1149-y
Zu, T. et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl Acad. Sci. USA 110, E4968–E4977 (2013).
pubmed: 24248382
pmcid: 3870665
doi: 10.1073/pnas.1315438110
Rigo, F. et al. Pharmacology of a central nervous system delivered 2′-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350, 46–55 (2014).
pubmed: 24784568
pmcid: 4056267
doi: 10.1124/jpet.113.212407
Eckstein, F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 24, 374–387 (2014).
pubmed: 25353652
doi: 10.1089/nat.2014.0506
Sztainberg, Y. et al. Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides. Nature 528, 123–126 (2015).
pubmed: 26605526
pmcid: 4839300
doi: 10.1038/nature16159
Becker, L. A. et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature 544, 367–371 (2017).
pubmed: 28405022
pmcid: 5642042
doi: 10.1038/nature22038
Tabrizi, S. J. et al. Targeting Huntingtin expression in patients with Huntington’s disease. N. Engl. J. Med. 380, 2307–2316 (2019).
pubmed: 31059641
doi: 10.1056/NEJMoa1900907
Moazami, M.P. et al. Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system. Preprint at https://www.biorxiv.org/content/10.1101/2021.02.14.431096v1 (2021).
Waite, A. J. et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol. Aging 35, 1779.e5–1779.e13 (2014).
doi: 10.1016/j.neurobiolaging.2014.01.016
Meng, L. et al. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature 518, 409–412 (2015).
pubmed: 25470045
doi: 10.1038/nature13975
Zhao, H. T. et al. LRRK2 antisense oligonucleotides ameliorate α-synuclein inclusion formation in a Parkinson’s disease mouse model. Mol. Ther. Nucleic Acids 8, 508–519 (2017).
pubmed: 28918051
pmcid: 5573879
doi: 10.1016/j.omtn.2017.08.002
Mohan, A. et al. Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain. Pain 159, 139–149 (2018).
pubmed: 28976422
doi: 10.1097/j.pain.0000000000001074
McCampbell, A. et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Invest. 128, 3558–3567 (2018).
pubmed: 30010620
pmcid: 6063493
doi: 10.1172/JCI99081
Tabrizi, S. J., Smith, A. V. & Bennett, C. F. Targeting Huntingtin in patients with Huntington’s disease. Reply. N. Engl. J. Med. 381, 1181–1182 (2019).
pubmed: 31532970
doi: 10.1056/NEJMc1910544
Aditi, Aditi, Folkmann, A. W. & Wente, S. R. Cytoplasmic hGle1A regulates stress granules by modulation of translation. Mol. Biol. Cell 26, 1476–1490 (2015).
pubmed: 25694449
pmcid: 4395128
doi: 10.1091/mbc.E14-11-1523
Jovicic, A. et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 18, 1226–1229 (2015).
pubmed: 26308983
pmcid: 4552077
doi: 10.1038/nn.4085
Zhang, Y. J. et al. Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nat. Med. 24, 1136–1142 (2018).
pubmed: 29942091
pmcid: 6520050
doi: 10.1038/s41591-018-0071-1
Yuva-Aydemir, Y., Almeida, S., Krishnan, G., Gendron, T. F. & Gao, F. B. Transcription elongation factor AFF2/FMR2 regulates expression of expanded GGGGCC repeat-containing C9ORF72 allele in ALS/FTD. Nat. Commun. 10, 5466 (2019).
pubmed: 31784536
pmcid: 6884579
doi: 10.1038/s41467-019-13477-8
Moens, T. G. et al. C9orf72 arginine-rich dipeptide proteins interact with ribosomal proteins in vivo to induce a toxic translational arrest that is rescued by eIF1A. Acta Neuropathol. 137, 487–500 (2019).
pubmed: 30604225
pmcid: 6514073
doi: 10.1007/s00401-018-1946-4
Coyne, A.N. et al. G
pubmed: 32673563
pmcid: 8077944
doi: 10.1016/j.neuron.2020.06.027
Kumar, R. et al. The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2′-thio-LNA. Bioorg. Med. Chem. Lett. 8, 2219–2222 (1998).
pubmed: 9873516
doi: 10.1016/S0960-894X(98)00366-7
DeVos, S.L. & Miller, T.M. Direct intraventricular delivery of drugs to the rodent central nervous system. J. Vis. Exp. e50326 (2013).
Tran, H. et al. Differential toxicity of nuclear RNA foci versus dipeptide repeat proteins in a Drosophila model of C9ORF72 FTD/ALS. Neuron 87, 1207–1214 (2015).
pubmed: 26402604
pmcid: 4589299
doi: 10.1016/j.neuron.2015.09.015
Shin, M., Krishnamurthy, P. M., Devi, G. & Watts, J. K. Quantification of antisense oligonucleotides by splint ligation and quantitative polymerase chain reaction. Nucleic Acid Ther. https://doi.org/10.1089/nat.2021.0040 (in the press) (2021).